Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations

• DOI: 10.1016/j.dmpk.2024.101024
• Publication Date: 2024-05-31T16:11:22Z
• Authors: Taichi Miyazaki; Daichi Hayashi; Akifumi Nozawa; Shiho Yasue; Saori Endo; Hidenori Ohnishi; Ryuta Asada; Mototoshi Kato; Akihiro Fujino; Tatsuo Kuroda; Takanobu Maekawa; Shigehisa Fumino; Naonori Kawakubo; Tatsuro Tajiri; Kenji Shimizu; Chihiro Sanada; Izumi Hamada; Yuko Ishikawa; Mayumi Hasegawa; Kashyap Patel; Yehua Xie; Michio Ozeki

A population pharmacokinetic (PopPK) analysis was conducted using data from 215 Japanese administered oral sirolimus (tablet and granule) including healthy subjects and patients with intractable vascular anomalies and other diseases. The analysis included neonates, infants, and adults, and identified covariates that influence sirolimus pharmacokinetics (PK). The final model was used to predict sirolimus trough concentrations for various dosing regimens and covariates of interest. The results showed that sirolimus trough concentrations were predicted to increase with higher levels of hemoglobin, and that the granule formulation had a 1.23-fold higher exposure than the tablet formulation. Coadministration of CYP3A4 inducers was found to decrease trough concentrations by 54 %. The PK simulations showed that administration of the granule formulation at doses of 0.02, 0.04, 0.06, and 0.08 mg/kg/day in ages <3 months, 3 to <6 months, 6 to <12 months, and ≥1 year, respectively, resulted in >70 % target attainment within the therapeutic trough concentration range (5-15 ng/mL). In conclusion, incorporation of time-varying covariates (body weight and age) into the PopPK model appropriately predicted sirolimus concentrations in Japanese subjects from infants to adult sub-populations. This PopPK model would therefore be able to provide a reference for clinical individualization of sirolimus dosing.